ライフサイエンスコーパス: and every * weeks thereafter

1 , 24 weeks, and 32 weeks of treatment from day 1 of cycle 1 and every 12 weeks thereafter.

2 Response to treatment was assessed at week 12 and every 8 weeks thereafter.

3 engagement (follow-up visit attendance at week 4, week 12, and every 12 weeks thereafter), refills, self-reported adhere

4 fliximab (5 mg/kg of body weight) at weeks 1, 3, 7, and 14, and every 8 weeks thereafter.

5 Patients completed questionnaires at baseline, week 17, and every 16 weeks thereafter until treatment discontinuation

6 -to-treat population, assessed every 6 weeks until month 18 and every 9 weeks thereafter.

7 ity-of-life instrument at baseline, weeks 4, 7, 10, and 24, and every 12 weeks thereafter up to 2 years, irrespective of

8 -HBV therapy were enrolled and followed up at weeks 12, 24, and every 24 weeks thereafter in a multicenter longitudinal c

9 4 weeks and FPG was measured at baseline, week 12, week 24, and every 24 weeks thereafter, and potential cases of new-ons

10 e weekly for weeks 1 to 8, every 2 weeks for weeks 9 to 24, and every 4 weeks thereafter until progression or unacceptabl

11 received ustekinumab 45 mg, which they continued at week 28 and every 12 weeks thereafter.

12 ramuscularly on day 1, followed by 250 mg on days 15 and 28 and every 4 weeks thereafter, and either lapatinib 1,500 mg o

13 V abatacept ( approximately 10 mg/kg) on days 1, 15, and 29 and every 4 weeks thereafter.

14 hereafter, 100 mg every 8 weeks, or 200 mg at weeks 0 and 4 and every 12 weeks thereafter) through week 40, placebo, or a

15 eks thereafter, 15 mg every 8 weeks, 50 mg at weeks 0 and 4 and every 12 weeks thereafter, 100 mg every 8 weeks, or 200 m

16 domly assigned to receive guselkumab (5 mg at weeks 0 and 4 and every 12 weeks thereafter, 15 mg every 8 weeks, 50 mg at

17 y in week 1 (10(6) plaque-forming units/mL), then in week 4 and every 2 weeks thereafter (10(8) plaque-forming units/mL).

18 Safety was assessed at weeks 2 and 4 and every 4 weeks thereafter; tumor response was evaluated ev

19 tekinumab, 90 mg ustekinumab, or placebo at week 0, week 4, and every 12 weeks thereafter.

20 or 1.5 mg BHT-3009, given intramuscularly at weeks 0, 2, 4, and every 4 weeks thereafter until week 44.

21 r visually matched placebo subcutaneously at weeks 0, 2, 4, and every 4 weeks thereafter.

22 Study visits were at baseline, weeks 2 and 4, and every 4 weeks thereafter.

23 mumab once weekly (cycles 1-2), every 2 weeks (cycles 3-6), and every 4 weeks thereafter (28-day cycles) until progressiv

24 wo cycles, then every 2 weeks for four cycles (cycles 3-6), and every 4 weeks thereafter.

25 ministered weekly (cycles 1-2), every 2 weeks (cycles 3-6), and every 4 weeks thereafter.

26 C) weekly in cycles 1 to 2, every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter for up to 2 years.

27 ximab or placebo infusions were given at weeks 0, 2, and 6, and every 8 weeks thereafter through week 46.

28 -label vedolizumab (300 mg) infusions at weeks 0, 2, and 6, and every 8 weeks thereafter through week 52 at tertiary cent

29 rilpivirine 900 mg (3 mL) intramuscularly at weeks 4 and 8, and every 8 weeks thereafter.

30 ssay in available samples at baseline (b; n = 472), week 9, and every 12 weeks thereafter.

31 mg every week for cycles 1-3, every 2 weeks for cycles 4-9, and every 4 weeks thereafter until disease progression or una

32 ploratory endpoint, PROs were assessed at baseline, week 9, and every 6 weeks thereafter using the European Organisation

33 Patients received 2 mg of IVT-AFL at baseline and every 4 weeks thereafter, until disease stability criteri

34 , weight, and waist circumference were measured at baseline and every 4 weeks thereafter.

35 by 3-day weighed food records) will be measured at baseline and every 4 weeks thereafter.

36 pia Treatment Study HOTV visual acuity protocol at baseline and every 9 weeks thereafter until no further improvement in

37 remelimumab (10 mg/kg) or placebo every 4 weeks for 7 doses and every 12 weeks thereafter until a treatment discontinuati

38 500 mg, or 8100 mg) every 2 weeks for the first 3 infusions and every 4 weeks thereafter.

39 0 mg given five times, administered at one 4 week interval, and every 8 weeks thereafter) or placebo.

40 23 mice (7 L1, 8 L2, 8 LC) were scanned at 1 month of life and every 4 weeks thereafter.

41 Response was assessed every 8 weeks for the first 6 months and every 12 weeks thereafter.

42 nsgenic (non-Tg) controls at 6-8 weeks of age (pre-plaque), and every 2 weeks thereafter until all mice were at least 16

43 ring the study for the first 12 months after randomisation, and every 12 weeks thereafter until study drug discontinuatio

44 ollow-up was every 3 weeks to 21 weeks after randomisation, and every 8 weeks thereafter.

45 Participants completed measures before randomization and every 2 weeks thereafter.

46 nd the intention-to-treat population, assessed at screening and every 12 weeks thereafter.

47 ously within 24 hours after cardiac-transplantation surgery and every two weeks thereafter, for a total of five doses, or

48 Follow-up blood cultures were obtained routinely at 4 weeks and every 8 weeks thereafter.

49 sly weekly for 8 weeks, then every other week for 16 weeks, and every 4 weeks thereafter; carfilzomib 56 mg/m(2) intraven

50 Courses were repeated at 4 and 8 weeks, and every 5 weeks thereafter.